Jane Endicott

Jane Endicott

Auto-generated profile, based on publicly available information

Jane Endicott

Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Newcastle University, Paul O’Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2004 in Science
Verified
Journal Article
Closed access
PDF file
MNMartin E. M. Noble
Martin E. M. Noble
JEJane A. Endicott
Jane A. Endicott
LJLouise N. Johnson
Louise N. Johnson
Protein kinases are targets for treatment of a number of diseases. This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available. Structures have informed drug design and have illuminated the mechanism of inhibition. We review progress with the receptor tyrosine kinases (growth factor receptors EGFR, VEGFR, and FGFR) and nonreceptor tyrosine kinases (Bcr-Abl), where advances have been made with cancer therapeutic agents such as Herceptin and Gleevec. Among the serine-threonine kinases, p38, Rho-kinase, cyclin-dependent kinases, and Chk1 have been targeted with productive results for inflammation and cancer. Structures have provided insights into targeting the inactive or active form of the kinase, for targeting the global constellation of residues at the ATP site or less conserved additional pockets or single residues, and into targeting noncatalytic domains.

1 May 1999 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
RHRalph Hoessel
Ralph Hoessel
SLSophie Leclerc
Sophie Leclerc
JEJane A. Endicott
Jane A. Endicott
MNMartin E. M. Nobel
Martin E. M. Nobel
ALAlison Lawrie
Alison Lawrie
LMLaurent Meijer
Laurent Meijer

1 December 1986 in Nature
Verified
Journal Article
Closed access
JGJames H. Gerlach
James H. Gerlach
JEJane A. Endicott
Jane A. Endicott
PJPeter F. Juranka
Peter F. Juranka
GHGraham Henderson
Graham Henderson
FSFarida Sarangi
Farida Sarangi
VLVictor Ling
Victor Ling

14 October 1999 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
NBNick R. Brown
Nick R. Brown
MNMartin E. M. Noble
Martin E. M. Noble
JEJane A. Endicott
Jane A. Endicott
LJLouise N. Johnson
Louise N. Johnson

7 July 2012 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
JEJane A. Endicott
Jane A. Endicott
MNMartin E.M. Noble
Martin E.M. Noble
LJLouise N. Johnson
Louise N. Johnson
Eukaryotic protein kinases are key regulators of cell processes. Comparison of the structures of protein kinase domains, both alone and in complexes, allows generalizations to be made about the mechanisms that regulate protein kinase activation. Protein kinases in the active state adopt a catalytically competent conformation upon binding of both the ATP and peptide substrates that has led to an understanding of the catalytic mechanism. Docking sites remote from the catalytic site are a key feature of several substrate recognition complexes. Mechanisms for kinase activation through phosphorylation, additional domains or subunits, by scaffolding proteins and by kinase dimerization are discussed.

5 September 2018 in Open Biology
Verified
Journal Article
Open access
DWDaniel J. Wood
Daniel J. Wood
JEJane A. Endicott
Jane A. Endicott
Since their characterization as conserved modules that regulate progression through the eukaryotic cell cycle, cyclin-dependent protein kinases (CDKs) in higher eukaryotic cells are now also emerging as significant regulators of transcription, metabolism and cell differentiation. The cyclins, though originally characterized as CDK partners, also have CDK-independent roles that include the regulation of DNA damage repair and transcriptional programmes that direct cell differentiation, apoptosis and metabolic flux. This review compares the structures of the members of the CDK and cyclin families determined by X-ray crystallography, and considers what mechanistic insights they provide to guide functional studies and distinguish CDK- and cyclin-specific activities. Aberrant CDK activity is a hallmark of a number of diseases, and structural studies can provide important insights to identify novel routes to therapy.